Nucor earnings beat by $0.08, revenue fell short of estimates
MINNEAPOLIS—Kristie Burns, the Senior Vice President of Marketing and Clinical Affairs at Tactile Systems Technology Inc . (NASDAQ:TCMD), recently sold a portion of her holdings in the company. According to a filing with the Securities and Exchange Commission, Burns sold 4,830 shares on February 24, 2025, at an average price of $14.6486 per share. This transaction totaled approximately $70,752. The sale comes as TCMD shares have declined about 13% over the past week, with the company currently valued at $359 million.
The sale was conducted to cover taxes associated with the settlement of stock units, as noted in the filing. Following this transaction, Burns retains ownership of 84,008 shares in the company.
In addition to the sale, Burns received a series of performance stock units (PSUs) and restricted stock units (RSUs) earlier in the month. On February 20, 2025, she was awarded 3,359 PSUs based on performance metrics from the previous year. Another allocation of 4,131 PSUs was granted, with vesting scheduled for 2026, contingent on the company’s performance in 2025. Additionally, 16,579 RSUs were granted, set to vest over a three-year period.
These transactions reflect Burns’ ongoing involvement with Tactile Systems Technology, a company specializing in surgical and medical instruments. InvestingPro analysis indicates the stock is currently trading below its Fair Value, with the company maintaining a "GREAT" financial health score and holding more cash than debt on its balance sheet.
In other recent news, Tactile Systems Technology reported robust financial results for the fourth quarter of 2024, with earnings per share (EPS) reaching $0.40, surpassing the forecast of $0.31. The company also achieved a revenue of $85.6 million, slightly above the expected $85.41 million, marking a 10.2% year-over-year growth. However, B.Riley analysts downgraded Tactile Systems from Buy to Neutral, lowering the price target to $18 from $23, due to concerns about slowing earnings growth and ongoing legal challenges. The company’s fiscal year 2025 guidance projects revenue between $316 million and $322 million, aligning with analysts’ expectations, but the adjusted EBITDA forecast of $35 million to $37 million falls short of the consensus of $45.2 million. Despite these challenges, Tactile Systems is focusing on expanding its lymphedema and airway clearance product lines. The company highlighted new product launches and innovations during its earnings call, emphasizing its commitment to improving patient access to care. Tactile Systems also faces ongoing qui tam lawsuits, which could pose potential risks. The company’s gross margin increased to 75.2% in Q4, reflecting operational efficiencies and strategic investments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.